Andra AP fonden cut its position in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 35.2% in the third quarter, Holdings Channel.com reports. The institutional investor owned 381,000 shares of the company’s stock after selling 206,900 shares during the period. Andra AP fonden’s holdings in Teva Pharmaceutical Industries were worth $2,621,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. First Interstate Bank purchased a new stake in Teva Pharmaceutical Industries during the second quarter valued at about $28,000. Pacer Advisors Inc. purchased a new stake in Teva Pharmaceutical Industries during the second quarter valued at about $32,000. AdvisorNet Financial Inc lifted its stake in Teva Pharmaceutical Industries by 71.3% during the third quarter. AdvisorNet Financial Inc now owns 3,665 shares of the company’s stock valued at $25,000 after buying an additional 1,525 shares in the last quarter. Kavar Capital Partners LLC purchased a new stake in Teva Pharmaceutical Industries during the second quarter valued at about $35,000. Finally, Motco purchased a new stake in Teva Pharmaceutical Industries during the third quarter valued at about $28,000. 54.10% of the stock is owned by institutional investors.
A number of equities analysts have recently weighed in on TEVA shares. Royal Bank of Canada reiterated a “hold” rating and issued a $10.00 target price on shares of Teva Pharmaceutical Industries in a report on Thursday, August 8th. ValuEngine downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Tuesday. SunTrust Banks dropped their target price on Teva Pharmaceutical Industries to $7.00 and set a “hold” rating on the stock in a report on Thursday, August 8th. Raymond James dropped their target price on Teva Pharmaceutical Industries from $22.00 to $15.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Finally, Wells Fargo & Co dropped their target price on Teva Pharmaceutical Industries from $17.00 to $8.00 and set a “market perform” rating on the stock in a report on Monday, September 30th. Five analysts have rated the stock with a sell rating, fourteen have given a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $11.22.
NYSE:TEVA opened at $10.26 on Tuesday. The stock’s 50 day moving average price is $8.96 and its 200 day moving average price is $8.37. Teva Pharmaceutical Industries Ltd has a 52 week low of $6.07 and a 52 week high of $22.02. The company has a market capitalization of $11.38 billion, a P/E ratio of 3.66, a P/E/G ratio of 1.12 and a beta of 1.82. The company has a debt-to-equity ratio of 1.62, a quick ratio of 0.56 and a current ratio of 0.89.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.56 EPS for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.02). Teva Pharmaceutical Industries had a positive return on equity of 15.41% and a negative net margin of 22.88%. The firm had revenue of $4.26 billion during the quarter, compared to analyst estimates of $4.25 billion. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries Ltd will post 2.26 earnings per share for the current fiscal year.
Teva Pharmaceutical Industries Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
See Also: What is a good dividend yield?
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.